Simultaneous disruption of TC-HR and alt-NHEJ with TRDMT1 inhibitor and PARP or Polymerase θ (POLθ) inhibitor kills cancer cells synergistically, providing a promising strategy to enhance the efficacy of PARP, POLθ and TRDMT1 targeted therapies. Here, PARP1 is linked to cancer.